Literature DB >> 17108098

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

Mirjam T Epping1, René Bernards.   

Abstract

Tumor antigens are of interest as diagnostic and prognostic markers and potential therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma (PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic marker for clinical outcome. It has been shown recently that PRAME functions as a repressor of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing interest in tumor antigens as targets for therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17108098     DOI： 10.1158/0008-5472.CAN-06-2522

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  27 in total

1.  TNIP1, a retinoic acid receptor corepressor and A20-binding inhibitor of NF-κB, distributes to both nuclear and cytoplasmic locations.

Authors:  Igor Gurevich; Carmen Zhang; Nidhish Francis; Brian J Aneskievich
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 2.  Corepressors of agonist-bound nuclear receptors.

Authors:  Igor Gurevich; Anthony M Flores; Brian J Aneskievich
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-14       Impact factor: 4.219

3.  PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Authors:  Gülçin Gezgin; Sietse J Luk; Jinfeng Cao; Mehmet Dogrusöz; Dirk M van der Steen; Renate S Hagedoorn; Daniëlle Krijgsman; Pieter A van der Velden; Matthew G Field; Gregorius P M Luyten; Karoly Szuhai; J William Harbour; Ekaterina S Jordanova; Mirjam H M Heemskerk; Martine J Jager
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

4.  A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Authors:  Aaron Y Chang; Tao Dao; Ron S Gejman; Casey A Jarvis; Andrew Scott; Leonid Dubrovsky; Melissa D Mathias; Tatyana Korontsvit; Victoriya Zakhaleva; Michael Curcio; Ronald C Hendrickson; Cheng Liu; David A Scheinberg
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

5.  CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade.

Authors:  Hongxia Yan; Xianglian Hou; Tianhang Li; Li Zhao; Xiaozhou Yuan; Hongjun Fu; Ruijie Zhu
Journal:  Tumour Biol       Date:  2016-10-05

6.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Authors:  Fabio Morandi; Maria Valeria Corrias; Isabella Levreri; Paola Scaruffi; Lizzia Raffaghello; Barbara Carlini; Paola Bocca; Ignazia Prigione; Sara Stigliani; Loredana Amoroso; Soldano Ferrone; Vito Pistoia
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

7.  Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?

Authors:  Miroslaw J Szczepanski; Theresa L Whiteside
Journal:  Biomark Med       Date:  2013-08       Impact factor: 2.851

8.  Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI).

Authors:  Manuela Hesse; Edith Willscher; Benjamin J Schmiedel; Stefan Posch; Ralph P Golbik; Martin S Staege
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

9.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Authors:  Vivian G Oehler; Katherine A Guthrie; Carrie L Cummings; Kathleen Sabo; Brent L Wood; Ted Gooley; Taimei Yang; Mirjam T Epping; Yaping Shou; Era Pogosova-Agadjanyan; Paula Ladne; Derek L Stirewalt; Janis L Abkowitz; Jerald P Radich
Journal:  Blood       Date:  2009-07-22       Impact factor: 22.113

10.  A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

Authors:  Mirjam T Epping; Liming Wang; Jane A Plumb; Michele Lieb; Hinrich Gronemeyer; Robert Brown; René Bernards
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.